Aeovian Pharmaceuticals Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$55M
- Investors
-
20
Aeovian Pharmaceuticals General Information
Description
Developer of biotechnology therapies intended to address inflammatory and degenerative diseases. The company's platform utilizes small molecule therapeutics to target key cellular pathways involved in inflammation and disease progression, incorporating advanced drug design, precision targeting, and optimized pharmacokinetics, enabling the healthcare industry to develop more effective treatments with improved safety profiles for patients suffering from chronic and debilitating conditions.
Contact Information
Website
www.aeovian.comCorporate Office
- 2930 Domingo Avenue
- Suite 145
- Berkeley, CA 94705
- United States
Corporate Office
- 2930 Domingo Avenue
- Suite 145
- Berkeley, CA 94705
- United States
Aeovian Pharmaceuticals Timeline
Aeovian Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series B) | 16-Dec-2025 | $55M | Completed | Generating Revenue | ||
| 5. Later Stage VC (Series A) | 13-May-2024 | Completed | Generating Revenue | |||
| 4. Grant | 31-Dec-2019 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A) | 03-Oct-2019 | Completed | Startup | |||
| 2. Later Stage VC | 15-May-2018 | $786K | Completed | Startup | ||
| 1. Seed Round | 27-Jun-2017 | $786K | $786K | Completed | Startup |
Aeovian Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-1 | ||||||||
| Series A | ||||||||
| Seed B | 8,950,191 | $0.000100 | 8% | $0.42 | $0.42 | 1x | $0.42 | 4.68% |
| Seed A | 1,277,831 | $0.000100 | 8% | $0.44 | $0.44 | 1x | $0.44 | 0.67% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Aeovian Pharmaceuticals Comparisons
Industry
Financing
Details
Aeovian Pharmaceuticals Competitors (3)
One of Aeovian Pharmaceuticals’s 3 competitors is Casma Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Casma Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Bach Pharma | Angel-Backed | Meredith, NH | ||||
| Longeveron | Formerly VC-backed | Miami, FL |
Aeovian Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aeovian Pharmaceuticals Patents
Aeovian Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026112516-A2 | Combo therapies using glp-1 and cd38 modulators | Pending | 21-Nov-2024 | ||
| WO-2026112516-A3 | Combo therapies using glp-1 and cd38 modulators | Pending | 21-Nov-2024 | ||
| WO-2026090190-A1 | Cd38 modulators and uses thereof | Pending | 22-Oct-2024 | ||
| AU-2024264337-A1 | Tricyclic fused imidazole compounds as cd38 modulators and uses thereof | Pending | 25-Apr-2023 | ||
| EP-4702026-A1 | Tricyclic fused imidazole compounds as cd38 modulators and uses thereof | Pending | 25-Apr-2023 | C07D498/04 |
Aeovian Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aeovian Pharmaceuticals Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CTI Life Sciences Fund | Venture Capital | Minority | ||
| Foresite Capital | Growth/Expansion | Minority | ||
| Luma Group | Accelerator/Incubator | Minority | ||
| SymBiosis (Bentonville) | Venture Capital | Minority | ||
| TSC Alliance Endowment Fund | Limited Partner | Minority |
Aeovian Pharmaceuticals FAQs
-
When was Aeovian Pharmaceuticals founded?
Aeovian Pharmaceuticals was founded in 2012.
-
Where is Aeovian Pharmaceuticals headquartered?
Aeovian Pharmaceuticals is headquartered in Berkeley, CA.
-
What is the size of Aeovian Pharmaceuticals?
Aeovian Pharmaceuticals has 8 total employees.
-
What industry is Aeovian Pharmaceuticals in?
Aeovian Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Aeovian Pharmaceuticals a private or public company?
Aeovian Pharmaceuticals is a Private company.
-
What is the current valuation of Aeovian Pharmaceuticals?
The current valuation of Aeovian Pharmaceuticals is .
-
What is Aeovian Pharmaceuticals’s current revenue?
The current revenue for Aeovian Pharmaceuticals is .
-
How much funding has Aeovian Pharmaceuticals raised over time?
Aeovian Pharmaceuticals has raised $143M.
-
Who are Aeovian Pharmaceuticals’s investors?
CTI Life Sciences Fund, Foresite Capital, Luma Group, SymBiosis (Bentonville), and TSC Alliance Endowment Fund are 5 of 20 investors who have invested in Aeovian Pharmaceuticals.
-
Who are Aeovian Pharmaceuticals’s competitors?
Casma Therapeutics, Bach Pharma, and Longeveron are competitors of Aeovian Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
